Cite
MLA Citation
D Gladman et al.. “FRI0489 Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the rapid-psa study.” Annals of the rheumatic diseases, vol. 76, n.d., p. 673. http://access.bl.uk/ark:/81055/vdc_100135162829.0x000061